Bladder Cancer

“The impressive duration of response, still expanding with 6/8 responses ongoing, is indicative of restoration of a lasting immunologic tumor control in advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA

The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.

The application is based on results from the phase 3 CheckMate-901 trial.

The designation, which will expedite the development and regulatory review of TAR-200 in this setting, is based on findings from the phase 2b SUNRISE-1 trial.

“[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma,” says Heather L. Huelster, MD.

The priority review is based on results from the phase 3 EV-302 trial.

Scott T. Tagawa, MD, MS, FACP, FASCO, offers a comprehensive look at the evolving treatment landscape, with a focus on practical considerations and ongoing research.

An overview of the toxicity profile of enfortumab vedotin and pembrolizumab in patients being treated for urothelial carcinoma.

Dr. Tagawa offers his initial impressions on the second patient case and discusses data on enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.

An expert on urothelial carcinoma reviews the case of a 76-year-old patient with advanced, resectable urothelial carcinoma.

Scott T. Tagawa, MD, MS, FACP, FASCO, a urothelial carcinoma specialist, discusses adverse events seen in patients receiving sacituzumab govitecan.

A medical oncologist specializing in urothelial carcinoma reviews key data on erdafitinib, enfortumab vedotin, and sacituzumab govitecan.

An expert on urothelial carcinoma gives an overview of disease risk factors, patient diagnosis, and testing practices.

Scott T. Tagawa, MD, MS, FACP, FASCO, presents the case of 72-year-old patient with metastatic urothelial carcinoma and offers his initial impressions.

The application is based on results from the phase 3 CheckMate-901 trial.

"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.

The FDA has accepted a resubmitted biologics license application for N-803 for use in combination with BCG for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

"Our data show no evidence of benefit from selenium and evidence of harm from vitamin E—a compound readily available over the counter," the authors write.

An approach combining chemotherapy and immunotherapy could help preserve quality of life.

"If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer," says Matthew Galsky, MD.

Treatment with adjuvant pembrolizumab reduced the risk of disease recurrence or death versus observation in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.

“In the bladder cancer field, there's been a renewed shift on looking at environmental exposures,” says Kyle A. Richards, MD, FACS.

"We're just trying to figure out ways to reduce our readmission rate, ways to reduce complications, and I think this is just a small step in doing that," says Randie White, MD.

“We wound up finding that there was no difference in recurrence, no difference in secondary events, and no difference in our survival end points whether or not you were exposed to Agent Orange,” says Kyle A. Richards, MD, FACS.

“I think one of the most interesting things that we found is that our readmission rate was about 40%,” says Randie White, MD.